Trellus Management Company, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Trellus Management Company, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	BUY	$3.84 - $9.74 $51,997 - $131,889	13,541 Added 4.73%	300,000 $2.49 Million
Q4 2021 Jan 31, 2022	BUY	$5.12 - $8.19 $216,975 - $347,075	42,378 Added 17.36%	286,459 $1.49 Million
Q2 2021 Jul 30, 2021	BUY	$7.82 - $9.23 $141,393 - $166,887	18,081 Added 8.0%	244,081 $2.08 Million
Q1 2021 May 03, 2021	BUY	$8.44 - $12.66 $165,390 - $248,085	19,596 Added 9.49%	226,000 $2 Million
Q4 2020 Feb 10, 2021	BUY	$7.98 - $12.29 $51,103 - $78,705	6,404 Added 3.2%	206,404 $2.54 Million

Q3 2020 Oct 20, 2020	BUY	$7.96 - $12.42 $168,759 - $263,316	21,201 Added 11.86%	200,000 $1.63 Million
Q2 2020 Aug 12, 2020	BUY	$5.4 - $13.37 $124,200 - $307,510	23,000 Added 14.76%	178,799 $1.72 Million
Q1 2020 May 06, 2020	BUY	$4.91 - $14.7 $451,469 - $1.35 Million	91,949 Added 144.01%	155,799 $1.06 Million
Q4 2019 Feb 20, 2020	SELL	$9.77 - $15.66 $206,635 - $331,209	-21,150 Reduced 24.88%	63,850 $951,000
Q3 2019 Nov 01, 2019	BUY	$9.59 - $12.0 $152,682 - $191,052	15,921 Added 23.05%	85,000 $871,000
Q2 2019 Jul 31, 2019	BUY	$9.54 - $14.96 $659,013 - $1.03 Million	69,079 New	69,079 $732,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $492M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Trellus Management Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Trellus Management Company, LLC with notifications on news.